Boston Scientific lands Euro nod for extended heart implant battery life

Wed, 11/21/2012 - 11:29am
Mass Device

European regulators approve updated labeling for several of Boston Scientific's implantable cardiac devices to reflect battery life potentials that the company says double some rival devices.

battery life illustration

Medical devices giant Boston Scientific (NYSE:BSX) this week won CE Mark approval in the European Union for updated labeling on several models of its implantable cardiac devices in recognition of battery life projections of up to 10 years in some cases.

European regulators allowed Boston Scientific to issue new labels with increased battery life projections for its Incepta, Energen, Punctua, Cognix and Teligen implants based on data submitted on each devices and its settings, according to a press release.


Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.